Last reviewed · How we verify
Armando Torres Ramírez — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tacrolimus with steroids minimization | Tacrolimus with steroids minimization | marketed | ||||
| CsA with steroid minimization | CsA with steroid minimization | marketed | ||||
| Tacrolimus with rapid steroid withdrawal | Tacrolimus with rapid steroid withdrawal | marketed | Calcineurin inhibitor | Calcineurin (protein phosphatase 2B) | Immunology / Transplantation |
Therapeutic area mix
- Immunology / Transplantation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Albert Einstein Healthcare Network · 1 shared drug class
- Allergan · 1 shared drug class
- Andrew B Adams · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Astellas Pharma China, Inc. · 1 shared drug class
- Astellas Pharma Europe Ltd. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Al-Azhar University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Armando Torres Ramírez:
- Armando Torres Ramírez pipeline updates — RSS
- Armando Torres Ramírez pipeline updates — Atom
- Armando Torres Ramírez pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Armando Torres Ramírez — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/armando-torres-ram-rez. Accessed 2026-06-09.